Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

被引:23
作者
Evans, Elizabeth A. [1 ]
Yoo, Caroline [2 ]
Huang, David [2 ]
Saxon, Andrew J. [3 ]
Hser, Yih-Ing [2 ]
机构
[1] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Hlth Promot & Policy, 312 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA
[2] Univ Calif Los Angeles, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, 11075 Santa Monica Blvd,Ste 200, Los Angeles, CA 90024 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA
关键词
Buprenorphine; Treatment acceptability; access; and utilization; Opioid use disorder; Pharmacotherapy; Longitudinal; MAINTENANCE TREATMENT; PATIENT PERSPECTIVES; METHADONE TREATMENT; ADDICTION; DEPENDENCE; RETENTION; OUTCOMES; MORTALITY; ABUSE; FACILITIES;
D O I
10.1016/j.jsat.2019.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Nationwide efforts seek to address the opioid epidemic by increasing access to medications for opioid use disorder (OUD), particularly with buprenorphine. A poorly understood challenge is that among individuals with OUD who do receive buprenorphine, many do not adhere to the pharmacotherapy long enough to achieve sustained benefits. We aimed to identify factors associated with buprenorphine treatment utilization over time. Methods: We used random-intercept modeling to identify factors associated with buprenorphine treatment utilization over 2 years after first follow-up by 789 individuals with OUD who had participated in a multi-site randomized clinical trial of buprenorphine compared to methadone. Key predictors were participants' reports of buprenorphine treatment accessibility and acceptability (assessed at first follow-up) and their interaction effects, controlling for baseline randomization status, sociodemographics, and other covariates. Results: Approximately 9.3-11.2% of participants utilized buprenorphine treatment over the 2 years of follow-up. Interaction effects indicated that individuals who perceived buprenorphine to be both accessible and acceptable were most likely to use buprenorphine during follow-up, controlling for other factors. In contrast, individuals who perceived buprenorphine to be unacceptable were least likely to use buprenorphine, regardless the level of perceived access to the medication. Buprenorphine treatment utilization was also negatively associated with Hispanic ethnicity, West coast context, and cumulative months receiving methadone treatment and incarceration during follow-up. Conclusions: To engage more individuals with OUD in long-term treatment with buprenorphine, interventions should target buprenorphine treatment acceptability, in addition to increasing buprenorphine access, and tailor efforts to meet the needs of vulnerable populations.
引用
收藏
页码:19 / 28
页数:10
相关论文
共 46 条
[1]  
[Anonymous], SAS ENT GUID 5 1
[2]   MAINTENANCE MEDICATION FOR OPIATE ADDICTION: THE FOUNDATION OF RECOVERY [J].
Bart, Gavin .
JOURNAL OF ADDICTIVE DISEASES, 2012, 31 (03) :207-225
[3]   Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment [J].
Bell, James ;
Trinh, Lieu ;
Butler, Bethany ;
Randall, Deborah ;
Rubin, George .
ADDICTION, 2009, 104 (07) :1193-1200
[4]   Management of opioid use disorder in the USA: present status and future directions [J].
Blanco, Carlos ;
Volkow, Nora D. .
LANCET, 2019, 393 (10182) :1760-1772
[5]   Opioid Addiction and Abuse in Primary Care Practice: A Comparison of Methadone and Buprenorphine as Treatment Options [J].
Bonhomme, Jean ;
Shim, Ruth S. ;
Gooden, Richard ;
Tyus, Dawn ;
Rust, George .
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2012, 104 (7-8) :342-350
[6]   A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia [J].
Burns, Lucy ;
Gisev, Natasa ;
Larney, Sarah ;
Dobbins, Timothy ;
Gibson, Amy ;
Kimber, Jo ;
Larance, Briony ;
Mattick, Richard P. ;
Butler, Tony ;
Degenhardt, Louisa .
ADDICTION, 2015, 110 (04) :646-655
[7]  
Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1
[8]  
DeFlavio JR, 2015, RURAL REMOTE HEALTH, V15
[9]  
Evans EA., 2019, TREATING OPIOID ADDI, P181, DOI [10.1007/978-3-030-16257-3_9, DOI 10.1007/978-3-030-16257-3_9]
[10]   Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10 [J].
Evans, Elizabeth ;
Li, Libo ;
Min, Jeong ;
Huang, David ;
Urada, Darren ;
Liu, Lei ;
Hser, Yih-Ing ;
Nosyk, Bohdan .
ADDICTION, 2015, 110 (06) :996-1005